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Abstract
Background: Most cervical cancer patients with pelvic recurrent or persistent disease are not candidates
for exenteration, therefore, they only receive palliative chemotherapy. Here we report the results of a
novel treatment modality for these patients pre-exenterative chemotherapy- under the rational that the
shrinking of the pelvic tumor would allow its resection.
Methods: Patients with recurrent or persistent disease and no evidence of systemic disease, considered
not be candidates for pelvic exenteration because of the extent of pelvic tumor, received 3-courses of
platinum-based chemotherapy. Response was evaluated by CT scan and bimanual pelvic examination;
however the decision to perform exenteration relied on the physical findings. Toxicity to chemotherapy
was evaluated with standard criteria. Survival was analyzed with the Kaplan-Meier method.
Results: Seventeen patients were studied. The median number of chemotherapy courses was 4. There
were 9 patients who responded to chemotherapy, evaluated by bimanual examination and underwent
pelvic exenteration. Four of them had pathological complete response. Eight patients did not respond and
were not subjected to surgery. One patient died due to exenteration complications. At a median follow-
up of 11 months, the median survival for the whole group was 11 months, 3 months in the non-operated
and 32 months in those subjected to exenteration.
Conclusion: Pre-exenterative chemotherapy is an alternative for cervical cancer patients that are no
candidates for exenteration because of the extent of the pelvic disease. Its place in the management of
recurrent disease needs to be investigated in randomized studies, however, its value for offering long-term
survival in some of these patients with no other option than palliative care must be stressed.
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Background
Cervical cancer continues to be an important health bur-
den with a yearly incidence of almost half a million new
cases in the world and a mortality rate of about 50% [1].
Currently, locally advanced disease is treated with concur-
rent cisplatin-based chemoradiation [2]. However,
approximately in 25% of all patients treated for cervical
carcinoma, the tumor will progress or recur locally [3,4],
being the most common site of recurrence the pelvis.
Thus, local relapse continues to be a significant problem
for these patients, as tumor persistence or local recurrence
in an irradiated pelvis indicates a very dismal prognosis
[5,6].
Recurrent disease can be treated by a) chemoradiation if the
primary disease was approached with surgery; b) palliative
chemotherapy if recurrence is considered unresectable and
the primary disease was treated with radiation or chemo-
radiation; and c) pelvic exenteration for selected cases with
small, central disease even if primarily treated with chem-
oradiation or radiation. Pelvic exenteration involves en
bloc resection of bladder, genital tract, and rectum; it was
first described by Brunschwig in 1948 [7]. This procedure
has curative potential in almost half of patients undergo-
ing this procedure [6] and it is commonly reserved for
only the small subgroup of recurrent disease patients who
meet the "standard" criteria for exenteration (small, cen-
tral tumors). However, most pelvic recurrences do show a
diffuse growth pattern fixed to one or both pelvic side
walls. These fixed recurrences are felt at physical examina-
tion as "pelvic fibrosis" with or without a dominant mass.
Thus, pelvic fibrosis, is an ominous finding significantly
related to nodal disease and fixation to pelvic side wall
[8].
Due to these facts, the vast majority of recurrent cervical
cancer patients are left with no curative options, therefore
it is important to search for other therapeutic alternatives
in patients that are not "standardly" considered for the
classical exenterative procedure. The introduction of high-
dose-rate intraoperative radiation therapy (HDR-IORT)
combined with radical surgical resection has widened the
scope of patients who may be offered surgery [9], how-
ever, this form of radiation delivery is not widely availa-
ble. In addition, despite this modality of treatment
provides a reasonable local control rate in patients who
have failed prior surgery and/or definitive radiation, only
those with complete gross resection at completion of sur-
gery appear to benefit from this radical approach in the
salvage setting [10].
Hokel et al., have recently described the laterally extended
endopelvic resection (LEER) as a novel surgical salvage
therapy to a selected subset of patients with locally
advanced and recurrent cervical carcinoma involving the
pelvic side wall. This consists in extending the lateral
resection plane of pelvic exenteration to the medial
aspects of the lumbosacral plexus, sacrospinous ligament,
acetabulum, and obturator membrane to allow for resec-
tion with disease-free margins [11]. With this salvage
approach, they have reported a 5-year survival probability
of 46% for those patients considered only for palliation
with current treatment options. Although these results are
highly encouraging, severe postoperative complications
occur in almost half of patients and the procedure is lim-
ited to tumors sized <5 cm with a recurrence-free interval
from primary radiation treatment of >5 months, and to
recurrences that do not involve the larger sciatic foramen;
all forms of parietal pelvic side wall disease are not suited
for this procedure [12].
Currently, a combination of cisplatin and paclitaxel has
shown better response rate and progression- free survival
than single agent cisplatin hence, combination chemo-
therapy as been regarded as the standard of care in
patients to be treated with systemic palliative chemother-
apy [13]. Chemotherapy however, as a definitive treat-
ment for recurrent cervical cancer has solely a palliative
role, with responses that are at best partial and of short
duration, as a consequence, almost all patients eventually
show progression and die from their disease. Because
objective responses are seen in almost a third of these
patients, we reasoned that a "local" consolidation would
potentially render some of these responding patients free
of disease. These observations prompted us to evaluate in
a pilot study, a treatment modality we have called "pre-
exenterative chemotherapy" in patients with "fixed" pel-
vic recurrence in the aimed to shrinking the pelvic recur-
rent tumor to then attempt, then, a "standard" pelvic
exenteration.
Methods
All patients had histologically proven persistent or recur-
rent cervical carcinoma to primary radiation or chemora-
diation. At the pelvic examination -under no anesthesia-,
these patients were felt to have pelvic fibrosis and diag-
nosed as having a recurrence of diffuse infiltrative growth
pattern (with or without a dominant mass) fixed or not to
one or both pelvic side walls. Consequently, these
patients were considered by the gynecologist team of our
Institution (C L-G, A G-E, GM) to be unsuitable for pelvic
exenteration regardless of the CT scan findings. Patients
also had to meet the following inclusion criteria: Aged
between 18 and 70 years; ECOG performance 0–1; ade-
quate hematological, hepatic and renal functions as deter-
mined by: hemoglobin equal or higher than 10 g/L,
leukocyte count higher than 4000/mm3, and a platelet
count of at least 100 000/mm3, total bilirubin less than
1.5 times the normal upper limit (NUL), transaminases
less than 1.5 times NUL, and normal levels of creatinineBMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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in serum; a normal posteroanterior chest X-ray as well as
having the correspondent informed consent. The exclu-
sion criteria included: severe systemic or uncontrolled dis-
ease (infection, central nervous system, metabolic, etc)
that precluded the use of chemotherapy and further
exenteration; concomitant treatment with any other
experimental drug; mental illness and previous or con-
comitant malignancies except non-melanoma skin can-
cer. The study was approved by the Institutional
Regulatory Boards.
Pre-exenterative chemotherapy
Chemotherapy was administered in an outpatient setting.
Diverse chemotherapy schedules based on cisplatin or
carboplatin were used as follows: Carboplatin AUC 5, d1,
paclitaxel 135 mg/m2, d1 and gemcitabine 800 mg/m2
d1&8 (2 patients); carboplatin AUC 5–6, d1, and paclit-
axel 135 mg/m2, d1 (3 patients); carboplatin AUC 5–6,
d1, and 5FU 1 gr/m2 d1-5, (3 patients); cisplatin 100 mg/
m2 d1, and 5FU 1 g/m2 d1-5, (4 patients); and cisplatin
100 mg/m2  d1 and gemcitabine 1 g/m2  d1&d8 (5
patients). Courses were administered every three weeks
for a maximum of 6 courses. Conventional antiemetic
therapy and ancillary medications were used during drug
treatment. Chemotherapy was stopped in cases of disease
progression or prohibitive toxicity.
Response and toxicity to pre-exenterative chemotherapy
Objective evaluation of response to chemotherapy using
standard response criteria was not the primary objective of
this study as this would have required that all patients had
a well-defined and measurable mass. Instead a response
to chemotherapy was defined when the pelvic disease was
felt less fixed and/or the "fibrosis" was felt softer by the
same team of gynecologists that performed the pre-chem-
otherapy evaluation. Toxicity to chemotherapy was evalu-
ated according to the NCI Common Toxicity Criteria.
Pelvic exenteration
After pre-exenterative chemotherapy, patients were evalu-
ated by the same team of gynecologists through pelvic
examination (CT scan was not mandatory). However, the
decision to proceed or not with the surgical procedure
relied only on pelvic examination and was based on
whether there was or not response as evaluated with
above described criteria. The other criterion for no
exenteration was a worsening of the general clinical con-
dition of the patient regardless of the pelvic examination.
Patients were followed every three months after comple-
tion of all treatment.
Survival
Overall survival was evaluated using the Kaplan-Meier
method and was considered from the date of the diagno-
sis of the persistent or recurrent disease until the date of
death of last visit.
Results
From May 1999 to March 2003, 17 patients were studied
in this pilot trial. Baseline characteristics of patients (at
diagnosis of their primary disease) are shown in Table 1.
The mean age of patients was 43.3 years and all, but two,
were squamous histology. FIGO stage distribution was as
follows: one patient was IB1, four were stage IB2, five IIB,
and seven, stage IIIB. Nine received radiation alone as the
definitive treatment of their primary disease, four were
treated with radiation plus extrafacial complementary
hysterectomy, and four patients received chemoradiation
with weekly cisplatin. A complete clinical response was
achieved in 13 patients after the primary treatment, three
had persistent disease and one progressed. All cases
accrued in this study had local pelvic relapse and the
median time to progression after primary treatment was
16 months (9–120) in the 13 cases that had complete
response, whereas the time to progression for the persist-
ent or progressive disease cases was 4 months (range 2–7
months).
All patients had histological confirmation of their recur-
rent disease. The clinical status at entering the study is
shown in Table 2. All patients complained of pelvic pain.
At physical pelvic exam the disease was felt as fixed to the
pelvic wall in all cases, 5 (29%) unilaterally and 12 (71%)
Table 1: Characteristics of patients
Number 17
Age 43.3 (29–55)
Histology
Squamous 15
Adenocarcinoma 2
FIGO Stage at diagnosis
1B1 1
1B2 4
IIB 5
IIIB 7
Primary Treatment
RT alone* 9
RT alone + Adj Hyst 4
Chemoradiation** 4
Response to Primary Treatment
Complete response 13
Persistence 3
Progression 1
Months to treatment failure
Recurrence (13 pts) 16 (9–120)
progression (4 pts) 4 (2–7)
* Radiation: 50Gy of external radiation plus brachytherapy to achieve 
at least 85Gy to point A. ** Six weekly applications of cisplatin at 40 
mg/m2 during external radiation.BMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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bilaterally. This was accompanied by unilateral leg edema
in six cases, hydronephrosis in three (18%) and both find-
ings: edema and hydronephrosis in three cases (18%).
Table 3 depicts the overall treatment received by the
patients. The median number of cycles delivered was four
(range 2–6 cycles). Evaluation of response following the
aforementioned subjective criteria, performed by biman-
ual pelvic examination, was achieved in nine patients and
these underwent the exenterative procedure. Among the
eight patients not exenterated, three showed progression
alone, one had clinical deterioration with no change at
pelvic examination and four had progression and clinical
deterioration. Objective response was also evaluated
using classical criteria in measurable disease (complete,
no evidence of disease, partial, >50 reduction in the prod-
uct of the two longest perpendicular diameters of the
measurable lesion; no change or stable, <50% decrease or
<25% increase, and progressive disease >25% increase).
According to this, within the 8 non-operated patients,
only four had pre and post-chemotherapy CT scans, three
had no response and one had progression. These data cor-
related well with that registered in the physical examina-
tion. On the contrary, in the nine operated patients, five
patients had pre and post-chemotherapy evaluation, and
all five had partial response. This, also correlates with that
perceived in the clinical examination. It is remarkable that
within the operable patients, in no case an objective com-
plete response was observed despite four cases had a path-
ological complete response. Figure 1 shows that in the
three cases with pathological complete response that had
pre and post chemotherapy CT scan there was residual
tumor after chemotherapy.
Chemotherapy was well tolerated. The most common side
effect were nausea/vomiting grade 1 and 2, mild to mod-
erate anemia was present in half of patients; all patients
presented leukopenia and neutropenia which were grade
3 in five and three patients respectively. There were no epi-
sodes of infection or bleeding (Table 4).
In regard to the exenterative procedure, a total infraeleva-
tor exenteration was done in eight cases and one had ante-
rior supraelevator exenteration. This patient was the one
with positive surgical margins in the vaginal border. It is
worth mentioning that, in this case, the transoperative
frozen section of the vaginal margin was reported nega-
tive; however, the definitive histological analysis showed
disease. The definitive histological analysis of the surgical
specimens showed a complete pathological response in 4
cases, a residual disease ≤2 cm in four cases, and one case
with a residual measuring 8 cm. In seven patients, the uri-
nary diversion consisted of an ileocolonic conduit and an
ileal conduit in two cases. Colostomy was done in the
eight cases undergoing total exenteration, (Table 5).
Regarding surgical morbidity, the mean surgical time was
6.3 hours (range 4.3–8); the mean of bleeding was 1860
mL (range 600–6000 mL). All patients required at least
one unit of red blood cells being the mean number of
units 3.4 (range 1–6). The mean hospital stay was 11.7
days (range 6–41), and the mean stay in the intensive care
unit was 1.8 days (0–12 days). Among the perioperative
and post-operative complications, one patient (11%) pre-
sented intestinal occlusion that resolved with non-opera-
tive measures, one had massive bleeding during the
surgery (11%), there was one case with urinary fistula
(11%) and two cases showed a perineal infection (22%).
One patient (11%) died at day 120 post-exenteration due
to sepsis. This patient was one of the four with a patholog-
ical complete response (Table 6).
All patients not subjected to exenteration showed disease
progression and died within the ensuing months, being
the median survival of only 3 months. The status of the
operated patients is as follows: patient 1: Path CR, alive
without disease at 62 months, patient 2: Path CR, alive
without disease 59 months; patient 3: Residual of 2 cm,
local and regional recurrence at 7 months post-exentera-
tion, patient 4: Residual of 2 cm, alive without disease 52
months, patient 5: residual of 2 cm, local recurrence at 10
months, patient 6: residual of 2 cm, local recurrence at 7
months, patient 7: Path CR died at four months from sur-
gical complications, patient 8: Path CR, died at 20 months
from liver recurrence; patient 9: Residual of 8 cm, alive
without disease 13 months. Thus, four of the nine oper-
Table 2: Clinical status of patients at entering the study
Sign/Symptom Number (%)
Pelvic pain 17 100
Fixation to pelvic side wall*
Unilateral 5 29
Bilateral 12 71
Ipsilateral leg edema 6 36
Hydronefrosis 3 18
Leg edema/hydronephrosis 3 18
* As determined by bimanual pelvic examination.
Table 3: Overall treatment
Median number of cycles 4
Exenterated 9
No exenterated 8
Reason for no exenteration
Progression 3
Clinical deterioration 1
Both 4BMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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ated patients are alive without disease. Median survival in
the intention to treat was 11 months, being 3 versus 32 in
the non-operated versus those that underwent exentera-
tion (Figures 2 and 3).
Discussion
Although pelvic exenteration plays a definitive role in the
management of recurrent cervical carcinoma, its impact in
terms of the proportion of cervical cancer patients who
benefit from such radical procedure has remained
unchanged because it continues to be indicated in only
very selected patients with small central pelvic recur-
rences. This fact, along with better medical support such
as routine use of prophylactic heparin, antibiotics, nutri-
Patients with complete pathological response post-chemotherapy Figure 1
Patients with complete pathological response post-chemotherapy. CT scans of 3 patients showing residual pelvic mass after 
chemotherapy. Images a,c,e show CT scans pre-treatment, and images b,d,f are the post-treatment control studies. Notably, a 
patient (images e-f) shows a residual post-chemotherapy pelvic mass measuring 9 × 5 cm.
Table 4: Toxicity to chemotherapy. (expressed by patient).
Toxicity Grades (%)
01 23 4
Nausea/Vomiting 0 10 6 1 0
Diarrhea 13 2 2 0 0
Neuropathy 15 1 1 0 0
Anemia 6 4 4 3 0
Leukopenia 0 3 9 5 0
Granulocytopenia 0 6 8 3 0
Thrombopenia 12 2 0 3 0BMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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tional support, and routine postoperative monitoring,
have reduced the morbidity from pelvic exenteration [14].
In order to increase the proportion of patients in whom
this salvage therapy could be attempted, we developed the
modality of "pre-exenterative chemotherapy" under the
rationale that systemic chemotherapy would allow the
obtaining free surgical margins in patients undergoing the
"standard" supra or infraelevator pelvic exenteration
operation in situations where the extent of pelvic disease
predicts that negative surgical margins would unlikely be
obtained. The results of this pilot study demonstrate the
feasibility of this approach, as nine (53%) out of the 17
patients included in this trial underwent pelvic exentera-
tion obtaining disease-free margins in all but one case;
four of them are alive without disease.
The clinical characteristics of the patients included in this
study are remarkable in the sense that all of them were
considered no suitable for pelvic exenteration according
to standard criteria by the team of gynecologists of our
Institution. This special subgroup of patients with recur-
rent disease is better defined if we look at their clinical
characteristics: 13 of them relapsed at a median time of
only 16 months whereas four were refractory to primary
treatment and progressed within two to seven months All
of them complained of pelvic pain, five had unilateral leg
edema, three presented hydronephrosis and three cases
had both signs. Both the short disease-free interval and
the presence of one or more of the typical triad of signs
and symptoms are either contraindications or factors pre-
dicting a very poor outcome after exenteration in most of
the reported series [15-20].
Selecting the true candidates for pelvic exenteration is a
difficult clinical dilemma in patients with recurrent cervi-
cal cancer after radiation therapy. Despite very thorough
preoperative investigation, inoperable disease is discov-
ered at the time of laparotomy in up to 50% of cases [21].
CT scanning is still one of the most extensively used
diagnostic tool, however it may be difficult to differentiate
recurrence from postoperative and post-radiation fibrosis
[22,23]. MRI has been regarded superior to CT scan in vis-
ualization of the tumor and parametrial invasion in pri-
mary tumors [24]; dynamic contrast-enhanced
subtraction MRI may differentiate between recurrent
tumor and benign conditions [25]. However, when MRI
has been used for determining surgical elegibility for pel-
vic exenteration its accuracy has been of 83% [26]. The
difficulties encountered by the common imaging meth-
ods for evaluating the extent of disease, such as CT scan
and MRI [27], have led to propose laparoscopy to select
candidates to undergo the procedure [28,29], which
proved to be effective as it may spare unnecessary laparot-
omy in half of the candidates patients [28].
It must be stressed, however, that all these imaging and
laparoscopy efforts to predict resectability and avoid
aborted exenterations are done in the setting of "classic
indications" of pelvic exenterations, where the ultimate
goals are increasing the efficacy of the procedure in terms
of disease control and decreased morbidity and mortality.
However, our approach in aimed at increasing the propor-
tion of patients in whom this salvage therapy could be
attempted under the rationale that systemic chemother-
apy would allow obtaining free surgical margins in situa-
tions where the extent of pelvic disease predicts that
negative surgical margins would unlikely be obtained and
therefore exenteration could not be offered to these
patients.
Table 5: Surgical data and pathological response
Exenterated 9
Total infraelevator 8
Anterior supraelevator 1
Pathological Response
Complete 4
Partial 5
≤ 2 cm residual 4
8 cm residual 1
Surgical margins
Negative 8
Positive 1
Ileocolonic conduit 7
Ileal conduit 2
Colostomy 8
Table 6: 
Surgical morbidity Mean Range
Surgical time 6.3 4.3–8
Bleeding 1860 mL 600–1600
Units transfused 3.4 1–6
Hospital stay 11-7 6–41
Intensive Care Unit stay 1.8 0–12
Complication (events)
Intestinal occlusion 1 (11%)
Massive bleeding 1 (11%)
Urinary fistula 1 (11%)
Perineal infection 2 (22%)
Death 1 (11%)*
The patient died (fistula and infection) at 4 months post-exenteration. 
This patient had pathological complete response.BMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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These considerations led us to rely on bimanual pelvic
examination, which is a subjective test, as our principal
criterion for deciding to perform the exenteration (as long
as there was no regional or systemic disease evaluated by
CT scan). We acknowledge that it would had been very
valuable to have an objective pre and post-chemotherapy
evaluation of the response by a CT scan, RMI, and/or PET
scan in all the cases, however, only nine cases had CT scan
pre and post therapy. Notwithstanding it is interesting to
notice that although all our patients were "felt" by physi-
cal exam to have side wall fixation, the CT scan confirmed
it only in six cases based on the criterion of having a less
than 3 mm separation of the tumor from the pelvic mus-
cles and/or vascular encasement [30]. It is important also
to notice that in the four cases that were not candidates for
exenteration after chemotherapy and had pre and post-
chemotherapy CT scans, there was no response in three
and progression in one, matching closely the findings of
bimanual pelvic examinations. In contrast, the five cases
that underwent exenteration and were felt to have
responded by physical examination, with the criteria
used, had partial responses according to the standard
WHO criteria suggesting that, after all, CT scan can be a
reliable method for evaluating the response to chemother-
apy in the setting of pelvic recurrences in a previously irra-
diated site.
Nevertheless, an important observation is the fact that in
three out of the four cases that achieved a pathological
complete response, the CT scan was clearly positive for the
presence of tumor. This is shown in figure 1, standing out
patient 3 (Figure 1e–f) in whom the residual mass after
Overall survival in the intention to treat; four out of 17 are alive for a median survival of 11 months Figure 2
Overall survival in the intention to treat; four out of 17 are alive for a median survival of 11 months.BMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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chemotherapy (1e) measured 9 × 5 cm. This finding might
suggest that exenteration could be useful after any degree
of response to chemotherapy because the actual response
to chemotherapy could be of greater magnitude than pre-
dicted by CT scan.
The use of chemotherapy in the palliative setting of per-
sistent or recurrent pelvic disease, particularly in a patient
who has received definitive radiation or chemoradiation
treatment has very limited value. In a review on results of
190 advanced or recurrent disease patients treated with 14
different chemotherapy protocols, the overall response
rate was 20.0% (4.2% complete response; 15.8% partial
response), with a median response duration of 4.8
months [31]. In a recent phase III study comparing cispl-
atin versus cisplatin paclitaxel, the response rate in the
subgroup with pelvic disease revealed onjective responses
in 14(21%) of 66 patients treated with cisplatin alone and
in 17(33%) of 52 patients treated with the combination,
however, median survival was the same, 8.8 months and
9.7 months, respectively [13]. The response reported here
using a platinum-based scheme was 55% (partial
responses) in the nine patients with pre and post-chemo-
therapy evaluation by CT scan, however it was only 29%
taking into account the 17 patients evaluated. This
response rate as well as the observed toxicity, is within the
range expected but no assumptions can be made on the
efficacy of any of the schemes used.
Survival in the operated and non-operated patients; median survival was 3 versus 32 months respectively Figure 3
Survival in the operated and non-operated patients; median survival was 3 versus 32 months respectively. This difference is 
highly significant.BMC Cancer 2005, 5:118 http://www.biomedcentral.com/1471-2407/5/118
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So far there is information of the efficacy of chemotherapy
in terms of pathological response in recurrent or advanced
cervical cancer because chemotherapy is only used as a
palliative measure and surgery is commonly not affered
after chemotherapy. Here we demonstrate a pathological
complete response rate of 44% in the nine patients treated
(23.5% taking into the 17 patients), which is higher than
obtained in neoadjuvant trials in locally advanced cervical
cancer utilizing platinum-based schemes with newer
drugs, such as gemcitabine [32,33], vinorelbine [34], pacl-
itaxel [35,36], and irinotecan [37]. It is worthwhile notic-
ing that the neoadjuvant trials with lower complete
response rates were those that subjected more patients to
surgery. The two studies with the lowest complete
responses, 16% and 17% operated 89% and 95% of
patients, respectively [35,36], whereas in the trial with
37.5% of complete response, the surgery rate was only
52% [34]. These data may explain our 44% of pathologi-
cal complete response rates, since only 52.9% of our
patients underwent surgery.
A noticeable finding of the present report is that the
median survival of 11 months compares favorably with
studies using systemic chemotherapy in the palliative set-
ting, ranging from 6 to 10 months [38,39]; however, we
must stress that half of patients (the non-operated) had a
median survival of only 3 months which suggest that the
patient population of patients had indeed very unfavora-
ble clinical characteristics. Of outmost importance is the
fact that from the operated patients four achieved patho-
logical complete response despite having tomographic
evidence of residual tumor and the median survival for
these 9 patients taken to exenterative surgery was 32
months. The fact that there was "gross persistent" disease
in the CT scan after chemotherapy support our view that
the overestimation of pelvic disease, either by pelvic
examination and/or imaging methods, hinder offering a
potentially curative surgery to a huge proportion of
patients with pelvic recurrence of cervical carcinoma. On
these bases, we are just to start a randomized study com-
paring pre-exenterative chemotherapy and exenteration
versus palliative chemotherapy alone in patients with pel-
vic disease that do not meet the criteria for pelvic
exenteration.
Conclusion
The therapeutic modality here reported, called pre-
exenterative chemotherapy, is a therapeutic alternative for
cervical cancer patients with recurrent or persistent disease
limited to the pelvis not usually considered candidates for
"classical" pelvic exenteration. Its value in the manage-
ment of recurrent disease needs to be confirmed in a ran-
domized phase III study.
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